SGLT-2 I in ADPKD? DAPA-PKD & STOP-PKD - Prof. Emilie Cornec Le Gall & Prof. Roman-Ulrich Müller скачать в хорошем качестве

SGLT-2 I in ADPKD? DAPA-PKD & STOP-PKD - Prof. Emilie Cornec Le Gall & Prof. Roman-Ulrich Müller

Prof. Emilie Cornec-Le Gall (Brest, France) and Prof. Roman-Ulrich Müller (Cologne, Germany) discuss the use of SGLT2 inhibition in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), focusing upon the DAPA-PKD and STOP-PKD studies, which have been initiated by Prof. Cornec-Le Gall and Prof. Müller. The study design of DAPA-PKD and STOP-PKD has been published in a review paper in Nephrology Dialysis Transplantation – NDT in 2025, which NDT‘s Editor-in-Chief, Dr. Hans-Joachim Anders, and MARKUS at HOMe Editors selected as the “NDT Paper of the Month” for a detailed MARKUS at HOMe discussion. Dr. Emilie Cornec-Le Gall is Professor of Nephrology in the Department of Nephrology at University of Brest (France) and Principal Investigator of DAPA-PKD. Dr. Roman-Ulrich Müller is Nephrologist at Uniklinik Köln (Cologne, Germany), Professor of Translational Nephrology at the University of Cologne and Principal Investigator of STOP-PKD. The interview was recorded on August 8th, 2025. Moderators: Prof. Dr. Andreas Kronbichler (Innsbruck, Austria), Dr. Sara Ksiazek (Vienna, Austria), Prof. Dr. Marcus Säemann (Vienna, Austria) and Prof. Dr. Gunnar Heine (Frankfurt am Main, Frankfurt, Germany). Articles discussed: SGLT2 inhibition for patients with ADPKD - closing the evidence gap. Müller RU, Guerrot D, Chonchol M, Schmitt R, Uchiyama K, Gansevoort RT, Cornec-Le Gall E. Nephrol Dial Transplant 2025 doi: 10.1093/ndt/gfaf061 Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trial. Cukoski S, Lindemann CH, Arjune S, Todorova P, Brecht T, Kühn A, Oehm S, Strubl S, Becker I, Kämmerer U, Torres JA, Meyer F, Schömig T, Hokamp NG, Siedek F, Gottschalk I, Benzing T, Schmidt J, Antczak P, Weimbs T, Grundmann F, Müller RU. Cell Rep Med 2023 doi: 10.1016/j.xcrm.2023.101283 Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure. Marton A, Saffari SE, Rauh M, Sun RN, Nagel AM, Linz P, Lim TT, Takase-Minegishi K, Pajarillaga A, Saw S, Morisawa N, Yam WK, Minegishi S, Totman JJ, Teo S, Teo LLY, Ng CT, Kitada K, Wild J, Kovalik JP, Luft FC, Greasley PJ, Chin CWL, Sim DKL, Titze J. J Am Coll Cardiol 2024 doi: 10.1016/j.jacc.2024.02.020 HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial. Bais T, Meijer E, Kramers BJ, Vart P, Vervloet M, Salih M, Bammens B, Demoulin N, Todorova P, Müller RU, Halbritter J, Paliege A, Gall EC, Knebelmann B, Torra R, Ong ACM, Karet Frankl FE, Gansevoort RT Trials 2024 doi: 10.1186/s13063-024-07952-x Chronic Kidney Disease of unexplained cause (CKDx): a consensus statement by the Genes & Kidney Working Group of the ERA. Halbritter J, Figueres L, Van Eerde AM, Capasso G, Hoorn EJ, Nijenhuis T, Perez-Gomez MV, Sayer JA, Simons M, Walsh S, Zagorec N, Müller RU, Cornec-Le Gall E Nephrol Dial Transplant 2025 doi: 10.1093/ndt/gfaf092